DICER1 syndrome

Overview

DICER1 syndrome is a rare genetic condition that predisposes individuals to an increased risk of developing certain tumours, most of which are uncommon in the general population [PMID:24555428]. These include pleuropulmonary blastoma (a lung tumour), cystic nephroma (a kidney growth), ovarian Sertoli-Leydig cell tumours, multinodular goitre and thyroid cancer, particularly of a type called differentiated thyroid carcinoma. The condition was first recognised when researchers noticed that certain rare childhood tumours seemed to cluster in families, prompting genetic investigations that identified DICER1 as the causative gene.

Not everyone with a pathogenic DICER1 variant will develop tumours, and the severity varies considerably between individuals, even within the same family [PMID:25611685]. Some people may experience multiple tumours across their lifetime, whilst others may never develop any clinical features. Because the condition is rare, exact prevalence figures are not well established, though it is thought to account for a meaningful proportion of certain rare paediatric malignancies when families are assessed through genetic testing. Early recognition through family history or genetic testing can enable surveillance programmes that may detect tumours at more treatable stages.

The range of tumours associated with DICER1 syndrome means that affected individuals and families require coordinated care across multiple specialties, often coordinated through clinical genetics services. Understanding one's genetic status helps families make informed decisions about surveillance and can inform reproductive choices for future generations.

Symptoms & clinical features

Clinical features of DICER1 syndrome depend on which organs develop tumours and at what age. Pleuropulmonary blastoma typically presents in early childhood, often before age six, with respiratory symptoms such as persistent cough, difficulty breathing, chest pain or recurrent chest infections. Some cases are detected incidentally on imaging performed for other reasons. Cystic nephroma, a benign kidney growth, may cause abdominal pain or a palpable mass, though it can also be asymptomatic and discovered during scans.

Thyroid involvement is common and may manifest as a multinodular goitre, often detected in adolescence or young adulthood. Affected individuals might notice swelling in the neck, difficulty swallowing or changes in voice. Ovarian Sertoli-Leydig cell tumours can cause abdominal pain, bloating or hormonal changes such as early development of male characteristics (virilisation). Other features reported in some individuals include nasal polyps, embryonal rhabdomyosarcoma (a soft tissue tumour), pituitary blastoma and certain eye abnormalities. The pattern and timing of symptoms vary considerably, and many people with a pathogenic DICER1 variant remain asymptomatic throughout life, particularly if tumours are detected early through surveillance.

Video: Is cancer in your genes?

Affected organs

DICER1 syndrome can affect multiple organ systems, reflecting the widespread role of microRNA regulation throughout the body. The lungs are particularly vulnerable, especially in young children who may develop pleuropulmonary blastoma. The kidneys can develop cystic nephroma or, less commonly, other renal tumours. The thyroid gland is frequently affected, with multinodular goitre and differentiated thyroid carcinoma occurring at higher rates than in the general population.

In females, the ovaries may develop Sertoli-Leydig cell tumours, typically during adolescence or young adulthood. Other organs occasionally affected include the uterus (cervix), brain (pituitary gland), nasal passages and various soft tissues where embryonal rhabdomyosarcoma can arise. The eye may rarely be involved, with conditions such as ciliary body medulloepithelioma reported in some families. Because DICER1 plays a fundamental role in gene regulation across tissues, the spectrum of potentially affected organs is broad, though certain sites show markedly increased tumour risk compared with the general population.

Multiple body systems

Systemic involvement

Cellular impact

Mechanism at cellular level

Risks & severity

The lifetime risk of developing one or more tumours in individuals with a pathogenic DICER1 variant is substantial, though precise figures remain uncertain due to the condition's rarity [PMID:26681312]. Research suggests that pleuropulmonary blastoma occurs in a minority of DICER1 variant carriers, typically presenting before age six. Cystic nephroma may develop in childhood or early adulthood. Thyroid disease, including multinodular goitre and cancer, affects a meaningful proportion of carriers, often becoming apparent during adolescence or adulthood. Ovarian Sertoli-Leydig cell tumours occur in females, usually between ages 10 and 30 years.

Severity is highly variable. Some individuals develop multiple tumours requiring surgical intervention and ongoing surveillance, whilst others carrying the same familial variant remain entirely unaffected. This incomplete penetrance means that genetic testing identifies at-risk individuals who may benefit from surveillance, but cannot predict with certainty who will develop tumours. Most DICER1-associated tumours are amenable to treatment when detected early, particularly through structured surveillance programmes, though outcomes depend on tumour type, location and stage at diagnosis. Pleuropulmonary blastoma, if not detected early, can be life-threatening, underscoring the importance of awareness among families and healthcare providers.

Genetic causes

DICER1 syndrome arises when pathogenic changes occur in the DICER1 gene, which encodes an enzyme critical for producing microRNAs [PMID:25533962]. These short RNA molecules regulate how much protein cells manufacture from various genes by attaching to messenger RNA and controlling translation. Acting like molecular scissors, the enzyme encoded by DICER1 processes longer precursor molecules into the mature, functional microRNAs that fine-tune protein production across virtually all cell types.

When pathogenic variants compromise this enzyme's function, the cell's regulatory machinery becomes disrupted. Protein levels may drift away from normal ranges, affecting fundamental processes such as growth control, cellular differentiation and programmed cell death. Evidence indicates that tumour development typically requires two separate genetic events: an inherited pathogenic variant affecting one gene copy, followed by a second somatic mutation acquired in specific cells during an individual's lifetime [PMID:24101671]. This acquired change often targets a particular functional region of the enzyme called the RNase IIIb domain, which is essential for processing microRNA precursors. This two-step mechanism helps explain why not all variant carriers develop tumours, and why malignancies arise in particular tissues rather than systemically. The altered microRNA environment in affected cells permits uncontrolled proliferation under certain circumstances, producing the characteristic tumour spectrum observed in this syndrome.

• DICER1
  dicer 1, ribonuclease III
  DICER1 encodes an enzyme that processes precursor RNA molecules into microRNAs, small regulatory molecules that control gene expression throughout the body.

Inheritance pattern

DICER1 syndrome follows an autosomal dominant pattern of inheritance. This means that inheriting one pathogenic variant in the DICER1 gene from either parent is sufficient to increase cancer risk. Each child of an affected parent has a 50% chance of inheriting the familial variant. Because the condition shows incomplete penetrance, some people who inherit the variant never develop tumours, whilst others in the same family may be significantly affected.

Many individuals diagnosed with DICER1 syndrome have inherited the variant from a parent, though family history may not be obvious if the parent remained asymptomatic or developed only mild features such as benign thyroid nodules. In some cases, the pathogenic variant arises de novo, meaning it occurred for the first time in the affected individual and was not inherited from either parent. Once present, however, the variant can be passed to future generations. Genetic counselling helps families understand recurrence risks, informs reproductive choices and guides decisions about predictive testing for at-risk relatives, including children who may benefit from early surveillance.

Diagnosis & testing

Diagnosis of DICER1 syndrome is confirmed through genetic testing that identifies a pathogenic or likely pathogenic variant in the DICER1 gene. Clinical suspicion may arise when an individual develops one of the characteristic tumours, particularly pleuropulmonary blastoma or cystic nephroma, or when a family history reveals multiple relatives with DICER1-associated features. Paediatric oncologists, endocrinologists or clinical geneticists may initiate referral for genetic assessment.

Within the NHS Genomic Medicine Service, individuals with suspected DICER1 syndrome or relevant family history can be referred to regional genetic services. Testing may be accessed through cancer predisposition gene panels that include DICER1, particularly when evaluating children with rare tumours or adults with suggestive family histories. Genetic counselling is an integral component of the diagnostic pathway, helping families understand test implications, surveillance recommendations and reproductive risks. Once a pathogenic variant is confirmed in a family, predictive testing can be offered to at-risk relatives, including children, to guide personalised surveillance strategies. Clinical criteria and testing eligibility are overseen by specialist genetic teams in line with national guidelines.

Management & lifestyle

Management of DICER1 syndrome centres on surveillance to detect tumours early, when treatment is most effective. Surveillance protocols typically include regular chest imaging (usually computed tomography scans) from early childhood to detect pleuropulmonary blastoma, renal ultrasound to monitor for cystic nephroma and thyroid ultrasound to identify nodules or thyroid cancer. Pelvic ultrasound may be recommended for females to screen for ovarian tumours. The specific schedule and modalities are individualised based on age, sex and family history, guided by clinical genetics and oncology teams.

When tumours are detected, treatment depends on type, location and stage. Surgical resection is often the primary approach for solid tumours such as pleuropulmonary blastoma, cystic nephroma and ovarian growths. Thyroid nodules require assessment, with surgery and radioactive iodine therapy considered for malignant lesions. Chemotherapy or radiotherapy may be required for certain tumour types. Ongoing surveillance continues after treatment, as individuals remain at risk for additional primary tumours. Genetic counselling supports informed decision-making about surveillance intensity, reproductive options including preimplantation genetic testing, and cascade testing of relatives. Lifestyle modifications have not been shown to meaningfully alter tumour risk in DICER1 syndrome, so management focuses on medical surveillance and early intervention.

UK care pathway

In the UK, individuals with suspected or confirmed DICER1 syndrome are typically managed through the NHS Genomic Medicine Service, with care coordinated by regional clinical genetics centres. Referral pathways may originate from paediatric oncology, endocrinology or primary care when clinical features or family history raise suspicion. Genetic testing is accessed through appropriate gene panels, and results are discussed in the context of genetic counselling to ensure families understand implications for surveillance and relatives.

Once a diagnosis is established, ongoing care involves multidisciplinary input from clinical geneticists, oncologists, endocrinologists, radiologists and specialist nurses. Surveillance protocols are tailored to the individual, with imaging schedules adjusted based on age and evolving evidence. Access to genetic counsellors supports families in navigating testing for at-risk relatives, understanding reproductive options and managing the psychological aspects of living with a cancer predisposition syndrome. Regional genetics services maintain long-term follow-up, updating surveillance recommendations as guidelines evolve and coordinating with specialist teams when tumours are detected.

Related conditions

DICER1 syndrome shares some clinical overlap with other cancer predisposition syndromes, particularly those affecting multiple organ systems. Conditions such as Cowden syndrome and PTEN hamartoma tumour syndrome can present with thyroid nodules and increased cancer risks, though the specific tumour spectrum differs. Familial adenomatous polyposis and Lynch syndrome are other hereditary cancer conditions, but these primarily affect the gastrointestinal tract rather than the lungs, kidneys and ovaries characteristic of DICER1 syndrome.

Pleuropulmonary blastoma, a hallmark of DICER1 syndrome, is rare and not typically associated with other genetic syndromes, helping distinguish DICER1 syndrome when this tumour type is identified. Cystic nephroma can occasionally occur sporadically or in other contexts, but its presence alongside thyroid disease or ovarian tumours strongly suggests DICER1 involvement. Genetic testing clarifies the diagnosis when clinical features overlap with other conditions, ensuring appropriate surveillance and management strategies are implemented. Understanding these distinctions helps families and clinicians navigate the diagnostic process and anticipate the specific risks relevant to DICER1 syndrome.

Frequently asked questions

References

1. Hansford JR, Das A, McGee RB. Update on Cancer Predisposition Syndromes and Surveillance Guidelines for Childhood Brain Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2024. PMID: 38573059
2. Schultz KAP, Nelson AT, Mallinger PHR. DICER1-Related Tumor Predisposition: Identification of At-risk Individuals and Recommended Surveillance Strategies. Clinical cancer research : an official journal of the American Association for Cancer Research. 2024. PMID: 39400264
3. Guillerman RP, Foulkes WD, Priest JR. Imaging of DICER1 syndrome. Pediatric radiology. 2019. PMID: 31620849
4. Hořínová V, Drábová K, Nosková H. DICER1 Syndrome. Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti. 2019. PMID: 31409088
5. Adam MP, Bick S, Mirzaa GM. DICER1-Related Tumor Predisposition. 1993. PMID: 24761742
6. Pishdad R, Barbesino G, Wirth LJ. Familial Thyroid Cancers Syndromes. Endocrinology and metabolism clinics of North America. 2025. PMID: 40716903
7. Goel H, Goel A. MicroRNA and Rare Human Diseases. Genes. 2024. PMID: 39457367
8. Watanabe T, Soeda S, Endo Y. Rare Hereditary Gynecological Cancer Syndromes. International journal of molecular sciences. 2022. PMID: 35163487